Effects of Motexafin gadolinium on tumor metabolism and radiation sensitivity

International Journal of Radiation Oncology Biology Physics

Volumn 49, Issue 5, 2001, Pages 1381-1390

  Xu, Su ^a   Zakian, Kristen ^a   Thaler, Howard ^a   Matei, Cornelia ^a   Alfieri, Alan ^b   Chen, Yuchun ^a   Koutcher, Jason A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Metabolism; Motexafin gadolinium; NMR; Radiosensitizer; Tumor

Indexed keywords

DRUG DOSAGE; METABOLISM; NUCLEAR MAGNETIC RESONANCE; PHOSPHATES; RADIATION; TUMORS;

RADIATION EFFICACY;

GADOLINIUM;

CREATINE PHOSPHATE; GADOLINIUM TEXAPHYRIN; NUCLEOSIDE TRIPHOSPHATE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CARCINOMA; CANCER GRAFT; CANCER RADIOTHERAPY; CANCER SIZE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; MALE; METABOLISM; MONITORING; MOUSE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RADIOSENSITIVITY; TIME; TUMOR; TUMOR GROWTH; TUMOR METABOLISM;

ANIMALS; ENERGY METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MAMMARY NEOPLASMS, ANIMAL; METALLOPORPHYRINS; MICE; MICE, INBRED C3H; PHOSPHORUS; PHOTOSENSITIZING AGENTS; RADIATION TOLERANCE; RADIOBIOLOGY; TIME FACTORS;

EID: 0035312794     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01566-2     Document Type: Conference Paper

References (40)

1. Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers
2. The hypoxic cell; A target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture
3. Response of human tumor cell lines in vitro to fractionated irradiation
4. The hazard of accelerated tumor clonogen repopulation during radiotherapy
5. Tumor hypoxia; Its impact on cancer therapy
6. Terminology in the description of drug-radiation interactions
7. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma
8. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
9. Acquired multicellular-mediated resistance to alkylating agents in cancer
10. Radiation Therapy Group clinical trials with misonidazole
11. Continuous intravenous infusions of bromodeoxyuridine as a clinical radiosensitizer
12. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors
13. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme
14. Radiation therapy oncology group clinical trials with misonidazaole
15. Final report of the Phase I trial of the hypoxic cell radiosensitizer SR 2508 (Etanidazole) radiation therapy oncology group 83-03
16. Clinical radiosensitization; Why it does and does not work
17. Pre-clinical evaluation of Gadolinium (III) Texaphyrin complex
18. Gadolinium (III) Texaphyrin; A tumor selective radiation sensitizer that is detectable by MRI
19. A phase I single dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging
20. In vivo animal studies with gadolinium (III) texaphyrin as a radiation sensitizer
21. A Phase 1B/II multi-dose trial of Gadolinium-texaphyrin, a radiation sensitizer that is detectable by MR imaging; Preliminary results on brain metastases
22. Re-evaluating gadolinium (III)texaphyrin as a radiosensitizing agent
23. Subcellular distribution of the radiation enhancer, Motexafin Gadolinium (Gd-Tex) using multi-pixel fluorescence microscopy in two cancer cell lines
24. Tumor response to ionizing radiation and combined 2-deoxy-D-glucose application in EATC tumor bearing mice; Monitoring of tumor size and microscopic observations
25. In vivo 31P NMR detection of Pentose Phosphate Pathway block and enhancement of radiation sensitivity with 6-aminonicotinamide
26. Testing of new hypoxic sensitizers in vivo
27. 31P NMR
28. Quantitative changes in tumor metabolism, partial pressure of oxygen and radiobiological oxygenation status post radiation
29. Radiation dose dependent changes in tumor metabolism measured by 31P NMR spectroscopy
30. 31P NMR changes with growth in radioresistant and radiosensitive tumors
31. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge
32. Glucose metabolism in RIF-1 tumors after reduction in blood flow; An in vivo 13C and 31P NMR study
33. Response-specific adriamycin sensitivity markers provided by in vivo 31P nuclear magnetic resonance spectroscopy in murine mammary adenocarcinomas
34. Intracellular acidosis in murine fibrosarcomas coincides with ATP depletion, hypoxia, and high levels of lactate and total Pi
35. Estimation of tumor oxygenation and metabolic rate using 31P MRS; Correlation of longitudinal relaxation with tumor growth rate and DNA synthesis
36. Radiation induced changes in phosphorous TR1 values in human melanoma xenografts studied by 31P MRS
37. Effects of hyperthermia on bioenergetic status and phosphorus T1s in human melanoma xenografts monitored by 321P MRS
38. Phenyledediamine induced hepatocyte toxicity redox cycling mediated oxidative stress without oxygen activation
39. Thiol mediated apoptosis in prostate carcinoma cells